BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Trial status

Accepting patients

Phase
Phase 1
Enrollment
130
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 11 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986453 is a study treatment that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize proteins found on myeloma cells more easily. This treatment targets two proteins found on myeloma cells, BCMA and GPRC5D.
  • Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
  • Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Part A

Not yet accepting

Part B, Cohort 1

Not yet accepting

Part B, Cohort 2

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.